Merck's Biggest Impact With Zepatier Approval May Be On HCV Pricing
Executive Summary
On the market after Harvoni and Viekira Pak, and for a limited population, Merck's success might depend on an access strategy to make HCV therapy more affordable for patients under both private sector and government health plans.